nodes	percent_of_prediction	percent_of_DWPC	metapath
Methazolamide—CYP2E1—Dacarbazine—pancreatic cancer	0.151	0.205	CbGbCtD
Methazolamide—CYP2E1—Tamoxifen—pancreatic cancer	0.12	0.163	CbGbCtD
Methazolamide—CYP2C19—Tamoxifen—pancreatic cancer	0.0755	0.102	CbGbCtD
Methazolamide—CYP2C9—Tamoxifen—pancreatic cancer	0.0627	0.085	CbGbCtD
Methazolamide—CYP2D6—Tamoxifen—pancreatic cancer	0.0574	0.0777	CbGbCtD
Methazolamide—CYP2D6—Erlotinib—pancreatic cancer	0.0488	0.0661	CbGbCtD
Methazolamide—CYP2C9—Fluorouracil—pancreatic cancer	0.0462	0.0626	CbGbCtD
Methazolamide—CYP3A4—Tamoxifen—pancreatic cancer	0.0365	0.0494	CbGbCtD
Methazolamide—CYP3A4—Erlotinib—pancreatic cancer	0.031	0.042	CbGbCtD
Methazolamide—CYP3A4—Irinotecan—pancreatic cancer	0.028	0.038	CbGbCtD
Methazolamide—CYP2D6—Doxorubicin—pancreatic cancer	0.0241	0.0326	CbGbCtD
Methazolamide—CYP3A4—Docetaxel—pancreatic cancer	0.0205	0.0278	CbGbCtD
Methazolamide—CYP3A4—Sunitinib—pancreatic cancer	0.0204	0.0277	CbGbCtD
Methazolamide—CYP3A4—Doxorubicin—pancreatic cancer	0.0153	0.0207	CbGbCtD
Methazolamide—Blood disorder—Sunitinib—pancreatic cancer	0.00391	0.0156	CcSEcCtD
Methazolamide—Melaena—Erlotinib—pancreatic cancer	0.00369	0.0147	CcSEcCtD
Methazolamide—Tingling sensation—Fluorouracil—pancreatic cancer	0.00321	0.0128	CcSEcCtD
Methazolamide—Melaena—Sunitinib—pancreatic cancer	0.00319	0.0127	CcSEcCtD
Methazolamide—Hepatic failure—Tamoxifen—pancreatic cancer	0.00308	0.0123	CcSEcCtD
Methazolamide—Hepatic failure—Erlotinib—pancreatic cancer	0.00305	0.0122	CcSEcCtD
Methazolamide—Haemolytic anaemia—Erlotinib—pancreatic cancer	0.00304	0.0121	CcSEcCtD
Methazolamide—Hepatic failure—Sunitinib—pancreatic cancer	0.00264	0.0105	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Erlotinib—pancreatic cancer	0.00247	0.00984	CcSEcCtD
Methazolamide—Pancytopenia—Tamoxifen—pancreatic cancer	0.00227	0.00907	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Sunitinib—pancreatic cancer	0.00214	0.00852	CcSEcCtD
Methazolamide—Photosensitivity—Fluorouracil—pancreatic cancer	0.00213	0.0085	CcSEcCtD
Methazolamide—Hepatic failure—Gemcitabine—pancreatic cancer	0.00212	0.00845	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Tamoxifen—pancreatic cancer	0.00212	0.00844	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Erlotinib—pancreatic cancer	0.00209	0.00835	CcSEcCtD
Methazolamide—CA9—gall bladder—pancreatic cancer	0.002	0.178	CbGeAlD
Methazolamide—Pancytopenia—Sunitinib—pancreatic cancer	0.00195	0.00777	CcSEcCtD
Methazolamide—Bone marrow depression—Epirubicin—pancreatic cancer	0.00186	0.00742	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Sunitinib—pancreatic cancer	0.00181	0.00723	CcSEcCtD
Methazolamide—Erythema multiforme—Tamoxifen—pancreatic cancer	0.00181	0.00723	CcSEcCtD
Methazolamide—Erythema multiforme—Erlotinib—pancreatic cancer	0.00179	0.00715	CcSEcCtD
Methazolamide—Bone marrow depression—Doxorubicin—pancreatic cancer	0.00172	0.00686	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Gemcitabine—pancreatic cancer	0.00171	0.00684	CcSEcCtD
Methazolamide—Dysgeusia—Tamoxifen—pancreatic cancer	0.00163	0.00652	CcSEcCtD
Methazolamide—Pancytopenia—Gemcitabine—pancreatic cancer	0.00156	0.00623	CcSEcCtD
Methazolamide—Erythema multiforme—Sunitinib—pancreatic cancer	0.00155	0.00619	CcSEcCtD
Methazolamide—Glycosuria—Epirubicin—pancreatic cancer	0.00155	0.00618	CcSEcCtD
Methazolamide—Pancytopenia—Fluorouracil—pancreatic cancer	0.00154	0.00613	CcSEcCtD
Methazolamide—Hepatic failure—Docetaxel—pancreatic cancer	0.0015	0.006	CcSEcCtD
Methazolamide—Blood disorder—Epirubicin—pancreatic cancer	0.0015	0.006	CcSEcCtD
Methazolamide—Leukopenia—Tamoxifen—pancreatic cancer	0.00149	0.00596	CcSEcCtD
Methazolamide—Photosensitivity reaction—Fluorouracil—pancreatic cancer	0.00148	0.00589	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Gemcitabine—pancreatic cancer	0.00145	0.0058	CcSEcCtD
Methazolamide—Glycosuria—Doxorubicin—pancreatic cancer	0.00143	0.00572	CcSEcCtD
Methazolamide—Discomfort—Tamoxifen—pancreatic cancer	0.0014	0.0056	CcSEcCtD
Methazolamide—Dysgeusia—Sunitinib—pancreatic cancer	0.0014	0.00558	CcSEcCtD
Methazolamide—Haematuria—Gemcitabine—pancreatic cancer	0.0014	0.00558	CcSEcCtD
Methazolamide—Blood disorder—Doxorubicin—pancreatic cancer	0.00139	0.00555	CcSEcCtD
Methazolamide—Agranulocytosis—Gemcitabine—pancreatic cancer	0.00137	0.00546	CcSEcCtD
Methazolamide—Agranulocytosis—Fluorouracil—pancreatic cancer	0.00135	0.00537	CcSEcCtD
Methazolamide—CA9—islet of Langerhans—pancreatic cancer	0.00131	0.116	CbGeAlD
Methazolamide—Anorexia—Tamoxifen—pancreatic cancer	0.0013	0.00518	CcSEcCtD
Methazolamide—Anorexia—Erlotinib—pancreatic cancer	0.00128	0.00512	CcSEcCtD
Methazolamide—Leukopenia—Sunitinib—pancreatic cancer	0.00128	0.0051	CcSEcCtD
Methazolamide—Erythema multiforme—Gemcitabine—pancreatic cancer	0.00125	0.00497	CcSEcCtD
Methazolamide—Convulsion—Sunitinib—pancreatic cancer	0.00124	0.00494	CcSEcCtD
Methazolamide—Melaena—Epirubicin—pancreatic cancer	0.00123	0.00489	CcSEcCtD
Methazolamide—Paraesthesia—Tamoxifen—pancreatic cancer	0.00122	0.00488	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Docetaxel—pancreatic cancer	0.00122	0.00485	CcSEcCtD
Methazolamide—Dyspepsia—Tamoxifen—pancreatic cancer	0.0012	0.00478	CcSEcCtD
Methazolamide—Dyspepsia—Erlotinib—pancreatic cancer	0.00119	0.00473	CcSEcCtD
Methazolamide—Decreased appetite—Tamoxifen—pancreatic cancer	0.00118	0.00472	CcSEcCtD
Methazolamide—Aplastic anaemia—Epirubicin—pancreatic cancer	0.00118	0.0047	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Tamoxifen—pancreatic cancer	0.00118	0.00469	CcSEcCtD
Methazolamide—Fatigue—Tamoxifen—pancreatic cancer	0.00117	0.00468	CcSEcCtD
Methazolamide—Decreased appetite—Erlotinib—pancreatic cancer	0.00117	0.00467	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Erlotinib—pancreatic cancer	0.00116	0.00464	CcSEcCtD
Methazolamide—Fatigue—Erlotinib—pancreatic cancer	0.00116	0.00463	CcSEcCtD
Methazolamide—Melaena—Doxorubicin—pancreatic cancer	0.00113	0.00453	CcSEcCtD
Methazolamide—Anorexia—Sunitinib—pancreatic cancer	0.00111	0.00443	CcSEcCtD
Methazolamide—Pancytopenia—Docetaxel—pancreatic cancer	0.00111	0.00442	CcSEcCtD
Methazolamide—Ill-defined disorder—Irinotecan—pancreatic cancer	0.00109	0.00436	CcSEcCtD
Methazolamide—Aplastic anaemia—Doxorubicin—pancreatic cancer	0.00109	0.00435	CcSEcCtD
Methazolamide—Urticaria—Tamoxifen—pancreatic cancer	0.00108	0.00431	CcSEcCtD
Methazolamide—Body temperature increased—Erlotinib—pancreatic cancer	0.00106	0.00425	CcSEcCtD
Methazolamide—Ill-defined disorder—Gemcitabine—pancreatic cancer	0.00106	0.00424	CcSEcCtD
Methazolamide—Malaise—Irinotecan—pancreatic cancer	0.00106	0.00423	CcSEcCtD
Methazolamide—Vertigo—Irinotecan—pancreatic cancer	0.00106	0.00422	CcSEcCtD
Methazolamide—Leukopenia—Irinotecan—pancreatic cancer	0.00105	0.0042	CcSEcCtD
Methazolamide—Paraesthesia—Sunitinib—pancreatic cancer	0.00105	0.00418	CcSEcCtD
Methazolamide—Photosensitivity—Epirubicin—pancreatic cancer	0.00104	0.00414	CcSEcCtD
Methazolamide—Malaise—Gemcitabine—pancreatic cancer	0.00103	0.00412	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Docetaxel—pancreatic cancer	0.00103	0.00412	CcSEcCtD
Methazolamide—Dyspepsia—Sunitinib—pancreatic cancer	0.00103	0.00409	CcSEcCtD
Methazolamide—Leukopenia—Gemcitabine—pancreatic cancer	0.00103	0.00409	CcSEcCtD
Methazolamide—Hepatic failure—Epirubicin—pancreatic cancer	0.00101	0.00404	CcSEcCtD
Methazolamide—Decreased appetite—Sunitinib—pancreatic cancer	0.00101	0.00404	CcSEcCtD
Methazolamide—Leukopenia—Fluorouracil—pancreatic cancer	0.00101	0.00402	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Sunitinib—pancreatic cancer	0.00101	0.00402	CcSEcCtD
Methazolamide—Fatigue—Sunitinib—pancreatic cancer	0.00101	0.00401	CcSEcCtD
Methazolamide—Discomfort—Irinotecan—pancreatic cancer	0.00099	0.00395	CcSEcCtD
Methazolamide—Asthenia—Tamoxifen—pancreatic cancer	0.000977	0.0039	CcSEcCtD
Methazolamide—Convulsion—Fluorouracil—pancreatic cancer	0.000977	0.0039	CcSEcCtD
Methazolamide—Agranulocytosis—Docetaxel—pancreatic cancer	0.000972	0.00388	CcSEcCtD
Methazolamide—Confusional state—Irinotecan—pancreatic cancer	0.000969	0.00386	CcSEcCtD
Methazolamide—Asthenia—Erlotinib—pancreatic cancer	0.000967	0.00386	CcSEcCtD
Methazolamide—Discomfort—Gemcitabine—pancreatic cancer	0.000964	0.00385	CcSEcCtD
Methazolamide—Anaphylactic shock—Irinotecan—pancreatic cancer	0.000961	0.00383	CcSEcCtD
Methazolamide—Photosensitivity—Doxorubicin—pancreatic cancer	0.00096	0.00383	CcSEcCtD
Methazolamide—Discomfort—Fluorouracil—pancreatic cancer	0.000948	0.00378	CcSEcCtD
Methazolamide—Hepatic failure—Doxorubicin—pancreatic cancer	0.000938	0.00374	CcSEcCtD
Methazolamide—Anaphylactic shock—Gemcitabine—pancreatic cancer	0.000936	0.00373	CcSEcCtD
Methazolamide—Diarrhoea—Tamoxifen—pancreatic cancer	0.000932	0.00372	CcSEcCtD
Methazolamide—Confusional state—Fluorouracil—pancreatic cancer	0.000928	0.0037	CcSEcCtD
Methazolamide—Body temperature increased—Sunitinib—pancreatic cancer	0.000922	0.00368	CcSEcCtD
Methazolamide—Diarrhoea—Erlotinib—pancreatic cancer	0.000922	0.00368	CcSEcCtD
Methazolamide—Anaphylactic shock—Fluorouracil—pancreatic cancer	0.00092	0.00367	CcSEcCtD
Methazolamide—Anorexia—Irinotecan—pancreatic cancer	0.000916	0.00365	CcSEcCtD
Methazolamide—CA7—digestive system—pancreatic cancer	0.000895	0.0796	CbGeAlD
Methazolamide—Anorexia—Gemcitabine—pancreatic cancer	0.000892	0.00356	CcSEcCtD
Methazolamide—Erythema multiforme—Docetaxel—pancreatic cancer	0.000884	0.00353	CcSEcCtD
Methazolamide—Anorexia—Fluorouracil—pancreatic cancer	0.000877	0.0035	CcSEcCtD
Methazolamide—Vomiting—Tamoxifen—pancreatic cancer	0.000866	0.00345	CcSEcCtD
Methazolamide—Paraesthesia—Irinotecan—pancreatic cancer	0.000863	0.00344	CcSEcCtD
Methazolamide—Rash—Tamoxifen—pancreatic cancer	0.000858	0.00342	CcSEcCtD
Methazolamide—Dermatitis—Tamoxifen—pancreatic cancer	0.000858	0.00342	CcSEcCtD
Methazolamide—Vomiting—Erlotinib—pancreatic cancer	0.000856	0.00342	CcSEcCtD
Methazolamide—Somnolence—Irinotecan—pancreatic cancer	0.000854	0.00341	CcSEcCtD
Methazolamide—Headache—Tamoxifen—pancreatic cancer	0.000853	0.0034	CcSEcCtD
Methazolamide—Rash—Erlotinib—pancreatic cancer	0.000849	0.00339	CcSEcCtD
Methazolamide—Dermatitis—Erlotinib—pancreatic cancer	0.000849	0.00338	CcSEcCtD
Methazolamide—Dyspepsia—Irinotecan—pancreatic cancer	0.000846	0.00337	CcSEcCtD
Methazolamide—Headache—Erlotinib—pancreatic cancer	0.000844	0.00337	CcSEcCtD
Methazolamide—Paraesthesia—Gemcitabine—pancreatic cancer	0.00084	0.00335	CcSEcCtD
Methazolamide—Asthenia—Sunitinib—pancreatic cancer	0.000837	0.00334	CcSEcCtD
Methazolamide—Decreased appetite—Irinotecan—pancreatic cancer	0.000835	0.00333	CcSEcCtD
Methazolamide—Somnolence—Gemcitabine—pancreatic cancer	0.000832	0.00332	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Irinotecan—pancreatic cancer	0.000829	0.00331	CcSEcCtD
Methazolamide—Fatigue—Irinotecan—pancreatic cancer	0.000828	0.0033	CcSEcCtD
Methazolamide—Paraesthesia—Fluorouracil—pancreatic cancer	0.000826	0.0033	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	0.000821	0.00327	CcSEcCtD
Methazolamide—Somnolence—Fluorouracil—pancreatic cancer	0.000818	0.00326	CcSEcCtD
Methazolamide—Decreased appetite—Gemcitabine—pancreatic cancer	0.000813	0.00324	CcSEcCtD
Methazolamide—Dyspepsia—Fluorouracil—pancreatic cancer	0.00081	0.00323	CcSEcCtD
Methazolamide—Nausea—Tamoxifen—pancreatic cancer	0.000809	0.00323	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	0.000808	0.00322	CcSEcCtD
Methazolamide—Fatigue—Gemcitabine—pancreatic cancer	0.000807	0.00322	CcSEcCtD
Methazolamide—Nausea—Erlotinib—pancreatic cancer	0.0008	0.00319	CcSEcCtD
Methazolamide—Decreased appetite—Fluorouracil—pancreatic cancer	0.0008	0.00319	CcSEcCtD
Methazolamide—Diarrhoea—Sunitinib—pancreatic cancer	0.000798	0.00318	CcSEcCtD
Methazolamide—Dysgeusia—Docetaxel—pancreatic cancer	0.000797	0.00318	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	0.000794	0.00317	CcSEcCtD
Methazolamide—Feeling abnormal—Irinotecan—pancreatic cancer	0.000792	0.00316	CcSEcCtD
Methazolamide—CA9—digestive system—pancreatic cancer	0.000786	0.0699	CbGeAlD
Methazolamide—Feeling abnormal—Gemcitabine—pancreatic cancer	0.000771	0.00308	CcSEcCtD
Methazolamide—Body temperature increased—Irinotecan—pancreatic cancer	0.000759	0.00303	CcSEcCtD
Methazolamide—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	0.000759	0.00303	CcSEcCtD
Methazolamide—CA2—gall bladder—pancreatic cancer	0.000758	0.0675	CbGeAlD
Methazolamide—Feeling abnormal—Fluorouracil—pancreatic cancer	0.000758	0.00302	CcSEcCtD
Methazolamide—Pancytopenia—Epirubicin—pancreatic cancer	0.000748	0.00298	CcSEcCtD
Methazolamide—Vomiting—Sunitinib—pancreatic cancer	0.000741	0.00296	CcSEcCtD
Methazolamide—Body temperature increased—Gemcitabine—pancreatic cancer	0.00074	0.00295	CcSEcCtD
Methazolamide—Rash—Sunitinib—pancreatic cancer	0.000735	0.00293	CcSEcCtD
Methazolamide—Dermatitis—Sunitinib—pancreatic cancer	0.000735	0.00293	CcSEcCtD
Methazolamide—Urticaria—Fluorouracil—pancreatic cancer	0.000731	0.00292	CcSEcCtD
Methazolamide—Headache—Sunitinib—pancreatic cancer	0.000731	0.00291	CcSEcCtD
Methazolamide—Leukopenia—Docetaxel—pancreatic cancer	0.000728	0.00291	CcSEcCtD
Methazolamide—Body temperature increased—Fluorouracil—pancreatic cancer	0.000727	0.0029	CcSEcCtD
Methazolamide—Photosensitivity reaction—Epirubicin—pancreatic cancer	0.000719	0.00287	CcSEcCtD
Methazolamide—Convulsion—Docetaxel—pancreatic cancer	0.000705	0.00281	CcSEcCtD
Methazolamide—Drowsiness—Epirubicin—pancreatic cancer	0.000702	0.0028	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	0.000696	0.00278	CcSEcCtD
Methazolamide—Nausea—Sunitinib—pancreatic cancer	0.000693	0.00276	CcSEcCtD
Methazolamide—Pancytopenia—Doxorubicin—pancreatic cancer	0.000692	0.00276	CcSEcCtD
Methazolamide—Asthenia—Irinotecan—pancreatic cancer	0.000689	0.00275	CcSEcCtD
Methazolamide—Asthenia—Gemcitabine—pancreatic cancer	0.000671	0.00268	CcSEcCtD
Methazolamide—Haematuria—Epirubicin—pancreatic cancer	0.00067	0.00267	CcSEcCtD
Methazolamide—Confusional state—Docetaxel—pancreatic cancer	0.00067	0.00267	CcSEcCtD
Methazolamide—Photosensitivity reaction—Doxorubicin—pancreatic cancer	0.000665	0.00265	CcSEcCtD
Methazolamide—Anaphylactic shock—Docetaxel—pancreatic cancer	0.000664	0.00265	CcSEcCtD
Methazolamide—Diarrhoea—Irinotecan—pancreatic cancer	0.000657	0.00262	CcSEcCtD
Methazolamide—Agranulocytosis—Epirubicin—pancreatic cancer	0.000655	0.00261	CcSEcCtD
Methazolamide—Drowsiness—Doxorubicin—pancreatic cancer	0.00065	0.00259	CcSEcCtD
Methazolamide—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	0.000644	0.00257	CcSEcCtD
Methazolamide—Diarrhoea—Gemcitabine—pancreatic cancer	0.00064	0.00255	CcSEcCtD
Methazolamide—Anorexia—Docetaxel—pancreatic cancer	0.000633	0.00252	CcSEcCtD
Methazolamide—Diarrhoea—Fluorouracil—pancreatic cancer	0.000629	0.00251	CcSEcCtD
Methazolamide—Haematuria—Doxorubicin—pancreatic cancer	0.00062	0.00247	CcSEcCtD
Methazolamide—Vomiting—Irinotecan—pancreatic cancer	0.000611	0.00244	CcSEcCtD
Methazolamide—CA5B—pancreas—pancreatic cancer	0.00061	0.0543	CbGeAlD
Methazolamide—Agranulocytosis—Doxorubicin—pancreatic cancer	0.000606	0.00242	CcSEcCtD
Methazolamide—Rash—Irinotecan—pancreatic cancer	0.000606	0.00242	CcSEcCtD
Methazolamide—Dermatitis—Irinotecan—pancreatic cancer	0.000605	0.00241	CcSEcCtD
Methazolamide—Headache—Irinotecan—pancreatic cancer	0.000602	0.0024	CcSEcCtD
Methazolamide—CA4—islet of Langerhans—pancreatic cancer	0.000599	0.0533	CbGeAlD
Methazolamide—Paraesthesia—Docetaxel—pancreatic cancer	0.000596	0.00238	CcSEcCtD
Methazolamide—Erythema multiforme—Epirubicin—pancreatic cancer	0.000596	0.00238	CcSEcCtD
Methazolamide—Vomiting—Gemcitabine—pancreatic cancer	0.000595	0.00237	CcSEcCtD
Methazolamide—Somnolence—Docetaxel—pancreatic cancer	0.00059	0.00235	CcSEcCtD
Methazolamide—Rash—Gemcitabine—pancreatic cancer	0.00059	0.00235	CcSEcCtD
Methazolamide—Dermatitis—Gemcitabine—pancreatic cancer	0.000589	0.00235	CcSEcCtD
Methazolamide—Tinnitus—Epirubicin—pancreatic cancer	0.000588	0.00234	CcSEcCtD
Methazolamide—Headache—Gemcitabine—pancreatic cancer	0.000586	0.00234	CcSEcCtD
Methazolamide—Vomiting—Fluorouracil—pancreatic cancer	0.000585	0.00233	CcSEcCtD
Methazolamide—Dyspepsia—Docetaxel—pancreatic cancer	0.000585	0.00233	CcSEcCtD
Methazolamide—CA12—digestive system—pancreatic cancer	0.000581	0.0517	CbGeAlD
Methazolamide—Rash—Fluorouracil—pancreatic cancer	0.00058	0.00231	CcSEcCtD
Methazolamide—Dermatitis—Fluorouracil—pancreatic cancer	0.00058	0.00231	CcSEcCtD
Methazolamide—Decreased appetite—Docetaxel—pancreatic cancer	0.000577	0.0023	CcSEcCtD
Methazolamide—Headache—Fluorouracil—pancreatic cancer	0.000576	0.0023	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	0.000573	0.00229	CcSEcCtD
Methazolamide—Fatigue—Docetaxel—pancreatic cancer	0.000572	0.00228	CcSEcCtD
Methazolamide—Nausea—Irinotecan—pancreatic cancer	0.000571	0.00228	CcSEcCtD
Methazolamide—Nausea—Gemcitabine—pancreatic cancer	0.000556	0.00222	CcSEcCtD
Methazolamide—Erythema multiforme—Doxorubicin—pancreatic cancer	0.000552	0.0022	CcSEcCtD
Methazolamide—Feeling abnormal—Docetaxel—pancreatic cancer	0.000547	0.00218	CcSEcCtD
Methazolamide—Nausea—Fluorouracil—pancreatic cancer	0.000546	0.00218	CcSEcCtD
Methazolamide—Tinnitus—Doxorubicin—pancreatic cancer	0.000544	0.00217	CcSEcCtD
Methazolamide—CA1—pancreas—pancreatic cancer	0.000539	0.048	CbGeAlD
Methazolamide—Dysgeusia—Epirubicin—pancreatic cancer	0.000537	0.00214	CcSEcCtD
Methazolamide—Body temperature increased—Docetaxel—pancreatic cancer	0.000525	0.00209	CcSEcCtD
Methazolamide—Ill-defined disorder—Epirubicin—pancreatic cancer	0.000509	0.00203	CcSEcCtD
Methazolamide—Dysgeusia—Doxorubicin—pancreatic cancer	0.000497	0.00198	CcSEcCtD
Methazolamide—CA2—islet of Langerhans—pancreatic cancer	0.000497	0.0442	CbGeAlD
Methazolamide—Malaise—Epirubicin—pancreatic cancer	0.000495	0.00197	CcSEcCtD
Methazolamide—Vertigo—Epirubicin—pancreatic cancer	0.000493	0.00197	CcSEcCtD
Methazolamide—Leukopenia—Epirubicin—pancreatic cancer	0.000491	0.00196	CcSEcCtD
Methazolamide—Asthenia—Docetaxel—pancreatic cancer	0.000476	0.0019	CcSEcCtD
Methazolamide—Convulsion—Epirubicin—pancreatic cancer	0.000475	0.0019	CcSEcCtD
Methazolamide—Ill-defined disorder—Doxorubicin—pancreatic cancer	0.000471	0.00188	CcSEcCtD
Methazolamide—Discomfort—Epirubicin—pancreatic cancer	0.000462	0.00184	CcSEcCtD
Methazolamide—CA1—digestive system—pancreatic cancer	0.00046	0.041	CbGeAlD
Methazolamide—Malaise—Doxorubicin—pancreatic cancer	0.000458	0.00183	CcSEcCtD
Methazolamide—Vertigo—Doxorubicin—pancreatic cancer	0.000456	0.00182	CcSEcCtD
Methazolamide—Leukopenia—Doxorubicin—pancreatic cancer	0.000455	0.00181	CcSEcCtD
Methazolamide—Diarrhoea—Docetaxel—pancreatic cancer	0.000454	0.00181	CcSEcCtD
Methazolamide—Confusional state—Epirubicin—pancreatic cancer	0.000452	0.0018	CcSEcCtD
Methazolamide—Anaphylactic shock—Epirubicin—pancreatic cancer	0.000448	0.00179	CcSEcCtD
Methazolamide—Convulsion—Doxorubicin—pancreatic cancer	0.00044	0.00175	CcSEcCtD
Methazolamide—Discomfort—Doxorubicin—pancreatic cancer	0.000427	0.0017	CcSEcCtD
Methazolamide—Anorexia—Epirubicin—pancreatic cancer	0.000427	0.0017	CcSEcCtD
Methazolamide—Vomiting—Docetaxel—pancreatic cancer	0.000422	0.00168	CcSEcCtD
Methazolamide—Rash—Docetaxel—pancreatic cancer	0.000419	0.00167	CcSEcCtD
Methazolamide—Dermatitis—Docetaxel—pancreatic cancer	0.000418	0.00167	CcSEcCtD
Methazolamide—Confusional state—Doxorubicin—pancreatic cancer	0.000418	0.00167	CcSEcCtD
Methazolamide—Headache—Docetaxel—pancreatic cancer	0.000416	0.00166	CcSEcCtD
Methazolamide—Anaphylactic shock—Doxorubicin—pancreatic cancer	0.000414	0.00165	CcSEcCtD
Methazolamide—Paraesthesia—Epirubicin—pancreatic cancer	0.000402	0.0016	CcSEcCtD
Methazolamide—Somnolence—Epirubicin—pancreatic cancer	0.000398	0.00159	CcSEcCtD
Methazolamide—Anorexia—Doxorubicin—pancreatic cancer	0.000395	0.00158	CcSEcCtD
Methazolamide—Nausea—Docetaxel—pancreatic cancer	0.000394	0.00157	CcSEcCtD
Methazolamide—Dyspepsia—Epirubicin—pancreatic cancer	0.000394	0.00157	CcSEcCtD
Methazolamide—Decreased appetite—Epirubicin—pancreatic cancer	0.000389	0.00155	CcSEcCtD
Methazolamide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	0.000387	0.00154	CcSEcCtD
Methazolamide—Fatigue—Epirubicin—pancreatic cancer	0.000386	0.00154	CcSEcCtD
Methazolamide—Paraesthesia—Doxorubicin—pancreatic cancer	0.000372	0.00148	CcSEcCtD
Methazolamide—Feeling abnormal—Epirubicin—pancreatic cancer	0.000369	0.00147	CcSEcCtD
Methazolamide—Somnolence—Doxorubicin—pancreatic cancer	0.000368	0.00147	CcSEcCtD
Methazolamide—Dyspepsia—Doxorubicin—pancreatic cancer	0.000365	0.00146	CcSEcCtD
Methazolamide—Decreased appetite—Doxorubicin—pancreatic cancer	0.00036	0.00144	CcSEcCtD
Methazolamide—CA4—digestive system—pancreatic cancer	0.00036	0.032	CbGeAlD
Methazolamide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	0.000358	0.00143	CcSEcCtD
Methazolamide—Fatigue—Doxorubicin—pancreatic cancer	0.000357	0.00143	CcSEcCtD
Methazolamide—Urticaria—Epirubicin—pancreatic cancer	0.000356	0.00142	CcSEcCtD
Methazolamide—Body temperature increased—Epirubicin—pancreatic cancer	0.000354	0.00141	CcSEcCtD
Methazolamide—CA2—pancreas—pancreatic cancer	0.000349	0.0311	CbGeAlD
Methazolamide—Feeling abnormal—Doxorubicin—pancreatic cancer	0.000342	0.00136	CcSEcCtD
Methazolamide—Urticaria—Doxorubicin—pancreatic cancer	0.000329	0.00131	CcSEcCtD
Methazolamide—Body temperature increased—Doxorubicin—pancreatic cancer	0.000328	0.00131	CcSEcCtD
Methazolamide—CYP2C19—digestive system—pancreatic cancer	0.000326	0.029	CbGeAlD
Methazolamide—Asthenia—Epirubicin—pancreatic cancer	0.000321	0.00128	CcSEcCtD
Methazolamide—Diarrhoea—Epirubicin—pancreatic cancer	0.000306	0.00122	CcSEcCtD
Methazolamide—CA2—digestive system—pancreatic cancer	0.000298	0.0265	CbGeAlD
Methazolamide—Asthenia—Doxorubicin—pancreatic cancer	0.000297	0.00119	CcSEcCtD
Methazolamide—Vomiting—Epirubicin—pancreatic cancer	0.000285	0.00114	CcSEcCtD
Methazolamide—Diarrhoea—Doxorubicin—pancreatic cancer	0.000284	0.00113	CcSEcCtD
Methazolamide—Rash—Epirubicin—pancreatic cancer	0.000282	0.00113	CcSEcCtD
Methazolamide—Dermatitis—Epirubicin—pancreatic cancer	0.000282	0.00113	CcSEcCtD
Methazolamide—Headache—Epirubicin—pancreatic cancer	0.000281	0.00112	CcSEcCtD
Methazolamide—Nausea—Epirubicin—pancreatic cancer	0.000266	0.00106	CcSEcCtD
Methazolamide—Vomiting—Doxorubicin—pancreatic cancer	0.000263	0.00105	CcSEcCtD
Methazolamide—Rash—Doxorubicin—pancreatic cancer	0.000261	0.00104	CcSEcCtD
Methazolamide—Dermatitis—Doxorubicin—pancreatic cancer	0.000261	0.00104	CcSEcCtD
Methazolamide—Headache—Doxorubicin—pancreatic cancer	0.00026	0.00104	CcSEcCtD
Methazolamide—CYP2C9—digestive system—pancreatic cancer	0.000252	0.0225	CbGeAlD
Methazolamide—Nausea—Doxorubicin—pancreatic cancer	0.000246	0.000982	CcSEcCtD
Methazolamide—CYP2E1—digestive system—pancreatic cancer	0.000239	0.0213	CbGeAlD
Methazolamide—CYP3A4—digestive system—pancreatic cancer	0.000193	0.0171	CbGeAlD
Methazolamide—CYP2D6—digestive system—pancreatic cancer	0.000189	0.0169	CbGeAlD
